Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
felzartamab (MOR202)
i
Other names:
MOR202, MOR03087, MOR-03087, MOR-202, TJ 202, HIB-202, TJ202, MOR 03087, MOR 202, TJ-202
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Biogen, Novartis, TJ Biopharma
Drug class:
CD38 inhibitor
Related drugs:
‹
daratumumab (26)
isatuximab-irfc (11)
daratumumab and hyaluronidase-fihj (4)
SAR442257 (4)
BHV-1100 (1)
ISB 1342 (1)
K-NK004 (1)
MT-0169 (1)
SAR442085 (1)
TAK-079 (1)
211At-OKT10-B10 (0)
FT538 (0)
FT555 (0)
FT576 (0)
GEN3014 (0)
IGM-2644 (0)
ISB 1442 (0)
ISB 2001 (0)
NY-338 (0)
SG2501 (0)
SG301 IV (0)
STI-1492 (0)
VP301 (0)
XmAb968 (0)
Y150 (0)
SAR650984 SC (0)
TAK-573 (0)
daratumumab (26)
isatuximab-irfc (11)
daratumumab and hyaluronidase-fihj (4)
SAR442257 (4)
BHV-1100 (1)
ISB 1342 (1)
K-NK004 (1)
MT-0169 (1)
SAR442085 (1)
TAK-079 (1)
211At-OKT10-B10 (0)
FT538 (0)
FT555 (0)
FT576 (0)
GEN3014 (0)
IGM-2644 (0)
ISB 1442 (0)
ISB 2001 (0)
NY-338 (0)
SG2501 (0)
SG301 IV (0)
STI-1492 (0)
VP301 (0)
XmAb968 (0)
Y150 (0)
SAR650984 SC (0)
TAK-573 (0)
›
Associations
(1)
News
Trials
VERI cancer hierarchy
Reset Filters
CD47 overexpression + CD38 underexpression
Multiple Myeloma
CD47 overexpression + CD38 underexpression
Multiple Myeloma
ABBV-IMAB-TJC4 + MOR202
Sensitive: D – Preclinical
ABBV-IMAB-TJC4 + MOR202
Sensitive
:
D
ABBV-IMAB-TJC4 + MOR202
Sensitive: D – Preclinical
ABBV-IMAB-TJC4 + MOR202
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login